CRYSTAL-VIS
A process analytical technology for characterising the physical properties of crystals
| Coordinatore | INNOPHARMA LABS LIMITED
Organization address
address: ASHFIELD CRONE LOWER contact info |
| Nazionalità Coordinatore | Ireland [IE] |
| Totale costo | 1˙513˙201 € |
| EC contributo | 1˙152˙987 € |
| Programma | FP7-SME
Specific Programme "Capacities": Research for the benefit of SMEs |
| Code Call | FP7-SME-2013 |
| Funding Scheme | BSG-SME |
| Anno di inizio | 2014 |
| Periodo (anno-mese-giorno) | 2014-01-01 - 2015-12-31 |
Partecipanti
| # | ||||
|---|---|---|---|---|
| 1 |
INNOPHARMA LABS LIMITED
Organization address
address: ASHFIELD CRONE LOWER contact info |
IE (REDCROSS) | coordinator | 521˙952.50 |
| 2 |
TOPCHEM PHARMACEUTICALS LIMITED
Organization address
address: BALLYMOTE BUSINESS PARK - CARROWNANTY contact info |
IE (BALLYMOTE SLIGO) | participant | 190˙225.00 |
| 3 |
J & M ANALYTIK AG
Organization address
address: WILLY MESSERSCHMITT STRASSE 8 contact info |
DE (ESSINGEN) | participant | 189˙045.00 |
| 4 |
NUTRARESEARCH 2011 SL
Organization address
address: C/FEIXA LLARGA 105 contact info |
ES (BARCELONA) | participant | 172˙545.00 |
| 5 |
LABIANA PHARMACEUTICALS SL
Organization address
address: CALLE CASANOVA 27 31 contact info |
ES (CORBERA DE LLOBREGAT) | participant | 48˙199.50 |
| 6 |
INNOVACIO I RECERCA INDUSTRIAL I SOSTENIBLE SL
Organization address
address: AVENIDA DEL CANAL OLIMPIC 15 PARC MEDITERRANI DE LA TECNOLOGIA EDIFICIO C4 BLOQUE ANEXO PLANTA BAJA contact info |
ES (Castelldefels) | participant | 12˙800.00 |
| 7 |
DUBLIN INSTITUTE OF TECHNOLOGY
Organization address
address: RATHMINES ROAD LOWER 143-149 contact info |
IE (DUBLIN) | participant | 11˙200.00 |
| 8 |
Teknologian tutkimuskeskus VTT Oy
Organization address
address: Vuorimiehentie 3 contact info |
FI (Espoo) | participant | 7˙020.00 |
| 9 |
RIKOLA LTD OY
Organization address
address: KAITOVAYLA 1 contact info |
FI (OULU) | participant | 0.00 |
| 10 |
TEKNOLOGIAN TUTKIMUSKESKUS VTT
Organization address
address: TEKNIIKANTIE 4 A contact info |
FI (ESPOO) | participant | 0.00 |
Mappa
Word cloud
Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.
Obiettivo del progetto (Objective)
'An active pharmaceutical ingredient (API) is the substance in a pharmaceutical drug that has the pharmacological activity. The crystallisation process is a critical step in the API manufacturing process and for delivering “product” in its final form, with some 70 % of products going through a crystallization step at some point in their manufacture. The size and shape of the crystals are important to the quality and safety of the product, and variation during crystal growth can have a significant effect on final product behaviour such as blend homogeneity, drug absorption rates, product robustness, etc. Controlling the final shape and size of crystal is a major challenge to manufacturers, particularly as it is often difficult to measure on line and the crystallisation process is often nonlinear in behaviour. Moreover, API molecules are becoming increasingly complex, tending to reduce aqueous solubility, in turn reducing bioavailability and often leading to difficulties in crystallisation. The ability to understand the crystallisation process would be a breakthrough for API manufacturers and would allow for control of the crystal phase, in terms of purity, particle size and shape, for high quality, safe products. Moreover, the crystal structure during crystal growth is a direct indicator of process end point and if more closely tracked could lead to leaner process development and process monitoring. Moreover, an understanding of crystallisation is fundamental for reducing the incidences of failure in the development of new molecular entities. A group of industrial SMEs have come together to outsource the development of a revolutionary imaging-based physical characterisation device that will provide the API industry with real-time information of all crystal physical characteristics in-line in a crystallisation process, thereby allowing this critical of processes for the behaviour of the end-product to be controlled'